Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Hormone-sensitive Metastatic Breast Cancer
Interventions: DRUG: OSI-906|DRUG: Erlotinib|DRUG: Letrozole|DRUG: Goserelin
Sponsor: Vanderbilt-Ingram Cancer Center